Abstract
Quetiapine, an atypical antipsychotic drug, is effective in treating the behavioral and psychological symptoms in Alzheimer’s disease (AD). However, it is presently unclear whether quetiapine has beneficial effects on memory and whether the effects of quetiapine on psychological symptoms are associated with its effect on memory in AD. The present study was designed to examine the effect of chronic administration of quetiapine on the conditioned (generalized) anxiety that is related to learning experience of open arm exposure in the elevated T-maze (ETM) test in an amyloid precursor protein (APP)/presenilin 1 (PS1) double transgenic mouse model of AD. In a 2nd experiment, the effect of quetiapine on memory per se was investigated in a Y-maze test in AD mice. Non-transgenic and transgenic mice were treated with quetiapine in drinking water from the age of 2 months. After continuous treatment with quetiapine (5 mg/kg/day) for 10 months, mice were tested for conditioned anxiety on the ETM task. After ETM testing, the expression of brain-derived neurotrophic factor (BDNF), a neuroprotective protein, was examined by immunohistochemistry in the basolateral amygdala (BLA) and hippocampus. In the 2nd experiment, the effect of quetiapine (2.5 or 5 mg/kg/day) on the short-term memory in AD mice was tested in a Y-maze test. After 10 months of administration, quetiapine prevented the decrease of conditioned anxiety and cerebral BDNF in AD mice. In addition, quetiapine also prevented memory impairment in the Y-maze test in AD mice. These findings suggest that the therapeutic mechanism of quetiapine on anxiety in AD may be associated with its beneficial effect on memory and its neuroprotective effect on cerebral BDNF expression.
Keywords: Alzheimer’s disease, APP/PS1 double transgenic mice, brain-derived neurotrophic factor, conditioned anxiety, memory, quetiapine
Current Alzheimer Research
Title:Quetiapine Modulates Conditioned Anxiety and Alternation Behavior in Alzheimer’s Transgenic Mice
Volume: 10 Issue: 2
Author(s): Adrien Tempier, Jue He, Shenghua Zhu, Ruiguo Zhang, Lynda Kong, Qingrong Tan, Huanmin Luo, Jiming Kong and Xin-Min Li
Affiliation:
Keywords: Alzheimer’s disease, APP/PS1 double transgenic mice, brain-derived neurotrophic factor, conditioned anxiety, memory, quetiapine
Abstract: Quetiapine, an atypical antipsychotic drug, is effective in treating the behavioral and psychological symptoms in Alzheimer’s disease (AD). However, it is presently unclear whether quetiapine has beneficial effects on memory and whether the effects of quetiapine on psychological symptoms are associated with its effect on memory in AD. The present study was designed to examine the effect of chronic administration of quetiapine on the conditioned (generalized) anxiety that is related to learning experience of open arm exposure in the elevated T-maze (ETM) test in an amyloid precursor protein (APP)/presenilin 1 (PS1) double transgenic mouse model of AD. In a 2nd experiment, the effect of quetiapine on memory per se was investigated in a Y-maze test in AD mice. Non-transgenic and transgenic mice were treated with quetiapine in drinking water from the age of 2 months. After continuous treatment with quetiapine (5 mg/kg/day) for 10 months, mice were tested for conditioned anxiety on the ETM task. After ETM testing, the expression of brain-derived neurotrophic factor (BDNF), a neuroprotective protein, was examined by immunohistochemistry in the basolateral amygdala (BLA) and hippocampus. In the 2nd experiment, the effect of quetiapine (2.5 or 5 mg/kg/day) on the short-term memory in AD mice was tested in a Y-maze test. After 10 months of administration, quetiapine prevented the decrease of conditioned anxiety and cerebral BDNF in AD mice. In addition, quetiapine also prevented memory impairment in the Y-maze test in AD mice. These findings suggest that the therapeutic mechanism of quetiapine on anxiety in AD may be associated with its beneficial effect on memory and its neuroprotective effect on cerebral BDNF expression.
Export Options
About this article
Cite this article as:
Tempier Adrien, He Jue, Zhu Shenghua, Zhang Ruiguo, Kong Lynda, Tan Qingrong, Luo Huanmin, Kong Jiming and Li Xin-Min, Quetiapine Modulates Conditioned Anxiety and Alternation Behavior in Alzheimer’s Transgenic Mice, Current Alzheimer Research 2013; 10 (2) . https://dx.doi.org/10.2174/1567205011310020010
DOI https://dx.doi.org/10.2174/1567205011310020010 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Serum Insulin Degrading Enzyme Level and Other Factors in Type 2 Diabetic Patients with Mild Cognitive Impairment
Current Alzheimer Research Anti-Inflammatory Properties of Drugs from saffron crocus
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Clinical Herbal Interactions with Conventional Drugs: From Molecules to Maladies
Current Medicinal Chemistry Editorial [ Medicines Da Vinci Code: Deciphering the Intricate Origins of Clinical Neurovascular Pathology K. Maiese ]
Current Neurovascular Research Biomarkers and Future Targets for Development in Amyotrophic Lateral Sclerosis
Current Medicinal Chemistry Targeting Heat Shock Protein 90 for Malaria
Mini-Reviews in Medicinal Chemistry Murine Models of Vpr-Mediated Pathogenesis
Current HIV Research Age-Related Neurodegeneration Prevention Through mTOR Inhibition: Potential Mechanisms and Remaining Questions
Current Topics in Medicinal Chemistry Markers of Atherosclerotic Disease: What do they Mean? Current Opinion and Future Trends
Current Pharmaceutical Design Effects of Early Maternal Separation on Biobehavioral and Neuropathological Markers of Alzheimer's Disease in Adult Male Rats
Current Alzheimer Research The Role of Microglial Cell Subsets in Alzheimers Disease
Current Alzheimer Research γ-Secretase as a Therapeutic Target for the Treatment of Alzheimers Disease
Current Pharmaceutical Design Cystatin C in Cerebrovascular Disorders
Current Neurovascular Research Protein Aggregation: Elucidation of the Mechanism and Determination of Associated Thermodynamic and Kinetic Parameters
Current Physical Chemistry Decreased Platelet APP Isoform Ratios in Autosomal Dominant Alzheimer’s Disease: Baseline Data from a DIAN Cohort Subset
Current Alzheimer Research Astrocytic Expression of the Immunoreceptor CD300f Protects Hippocampal Neurons from Amyloid-β Oligomer Toxicity In Vitro
Current Alzheimer Research Chronic Stress and Alzheimers Disease-Like Pathogenesis in a Rat Model: Prevention by Nicotine
Current Neuropharmacology Apolipoprotein E4 Serum Concentration for Increased Sensitivity and Specificity of Diagnosis of Drug Treated Alzheimer’s Disease Patients vs. Drug Treated Parkinson’s Disease Patients vs. Age-matched Normal Controls
Current Alzheimer Research Perioperative Considerations in Diabetic Patients
Current Diabetes Reviews The Spleen Tyrosine Kinase (Syk) in Human Disease, Implications for Design of Tyrosine Kinase Inhibitor Based Therapy
Current Pharmaceutical Design